Tag: sglt2 inhibitors

Click here to read this study in the Lancet.  ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...

In this population cohort study, patients with gout who used sodium-glucose cotransporter-2 inhibitors (SGLT2is) experienced fewer recurrent flares than those ...

1. Empagliflozin led to a lower risk of kidney disease progression in patients with chronic kidney disease (CKD) as compared ...

1. Dapagliflozin reduced the risk of hospitalization in patients with chronic kidney disease (CKD) with and without type 2 diabetes ...

1. SGLT2 inhibitors reduced the risk of kidney disease progression by 37% overall, with comparable effects in patients with and ...

1. For sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP1) receptor agonists to be used as first-line agents for type ...

1. This population-based cohort study demonstrated that among older adults with type 2 diabetes, sodium-glucose cotransporter-2 inhibitor (SGLT-2i) use was ...

1. Dapagliflozin was shown to reduce the risk of disease progression and cardiovascular death in patients with a mildly reduced ...

1. The use of sodium-glucose transport protein 2 inhibitors in patients with type 2 diabetes was associated with a lowered ...

1. Sotagliflozin was shown to lower the risk of total number of deaths from cardiovascular causes and hospitalizations and urgent ...